Abnormal striatal dopamine transmission in schizophrenia

Current Medicinal Chemistry

Volumn 20, Issue 3, 2013, Pages 397-404

  Brunelin, Jerome ^a,b,c   Fecteau, Shirley ^c,d   Suaud Chagny, Marie Françoise ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b CH Le Vinatier ^*  (France)

^c CENTER FOR INTERDISCIPLINARY RESEARCH IN REHABILITATION AND SOCIAL INTEGRATION   (Canada)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dopamine; Imaging; PET; Schizophrenia; Striatum

Indexed keywords

AMPHETAMINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE TRANSPORTER;

ARTICLE; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; HUMAN; MENTAL STRESS; NEUROANATOMY; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PSYCHOSIS; RECEPTOR DENSITY; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84877980569     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986713804870819     Document Type: Article

References (91)

1. Carlsson, A.; Lindqvist, M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh.), 1963, 20, 140-144.
2. Grace, A.A.; Bunney, B.S. The control of firing pattern in nigral dopamine neurons: single spike firing. J. Neurosci., 1984, 4, 2866-2876. (Pubitemid 15224431)
3. Sanghera, M.K., Trulson, M.E.; German, D.C. Electrophysiological properties of mouse dopamine neurons: in vivo and in vitro studies. Neuroscience, 1984, 12, 793-801. (Pubitemid 14092493)
4. Dugast, C.; Brun, P.; Sotty, F.; Renaud, B.; Suaud-Chagny M.F. On the involvement of a tonic dopamine D2-Autoinhibition in the regulation of pulse-to-pulse-evoked dopamine release in the rat striatum in vivo. Naunyn Schmiedeberg Arch. Pharmacol., 1997, 355, 716-719. (Pubitemid 27395697)
5. Grace, A.A.; Bunney, B.S. The control of firing pattern in nigral dopamine neurons: burst firing. J. Neurosci., 1984, 4, 2877-2890. (Pubitemid 15224432)
6. Freeman, A.S.; Bunney, B.S. Chronic neuroleptic effects on dopamine neuron activity: a model for predicting therapeutic efficacy and side effects? Psychopharmacol Ser., 1987, 3, 225-235.
7. Dugast, C.; Suaud-Chagny, M.F.; Gonon, F. Continuous in vivo monitoring of evoked dopamine releasein the rat nucleus accumbens by amperometry. Neuroscience, 1994, 62, 647-654. (Pubitemid 24325643)
8. Chergui, K.; Suaud-Chagny, M.F.; Gonon, F. Nonlinear relationship between impulse flow, dopamine release and dopamine elimination in the rat brain in vivo. Neuroscience, 1994, 62, 641-645.
9. Kiyatkin, E.A.; Rebec, G.V. Heterogeneity of ventral tegmental area neurons: single-unit recording and iontophoresis in awake, unrestrained rats. Neuroscience, 1998, 85(4), 1285-1309. (Pubitemid 28293430)
10. Suaud-Chagny, M.F.; Buda, M.; Gonon F. Pharmacology of electrically evoked DA release studied in the rat olfactory tubercle by in vivo electrochemistry. Eur. J. Pharmacol, 1989, 164, 273-283. (Pubitemid 19138634)
11. Suaud-Chagny, M.F.; Ponec, J.; Gonon, F. Presynaptic autoinhibition of the electrically evoked dopamine release studied in the rat olfactory tubercle by in vivo electrochemistry. Neuroscience, 1991, 45, 641-652.
12. Suaud-Chagny, M.F.; Dugast, C.; Chergui, K.; Msghina, M.; Gonon, F. Uptake of dopamine released by impulse flow in the rat mesolimbic and striatal systems in vivo. J. Neurochem., 1995, 65, 2603-2611.
13. Suaud-Chagny, M.F. In vivo monitoring of dopamine overflow in the central nervous system by amperometric techniques combined with carbon fibre electrodes. Methods, 2004, 33, 322-329.
14. Grace, A.A. Phasic versus tonis dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience, 1991, 41, 1-24.
15. Brown, W.D.; Taylor, M.D.; Roberts, A.D.; Oakes, T.R.; Schueller, M.J.; Holden, J.E.; Malischke, L.M.; DeJesus, O.T.; Nickles, R.J. FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology, 1999, 53, 1212-1218. (Pubitemid 29480078)
16. Pate, B.D.; Kawamata, T.; Yamada, T.; McGeer, E.G.; Hewitt, K.A.; Snow, B.J.; Ruth, T.J.; Calne, D.B. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol., 1993, 34, 331-338. (Pubitemid 23259601)
17. Snow, B.J.; Tooyama, I.; McGeer, E.G.; Yamada, T.; Calne, D.B.; Takahashi, H.; Kimura, H. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol., 1993, 34, 324-330. (Pubitemid 23259600)
18. Fischman, A.J. Role of [18F]-dopa-PET imaging in assessing movement disorders. Radiol. Clin. North Am., 2005, 43(1), 93-106. (Pubitemid 40326562)
19. Meyer-Lindenberg, A.; Miletich, R.S.; Kohn, P.D., et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci., 2002, 5, 267-271. (Pubitemid 34171141)
20. McGowan, S.; Lawrence, A.D.; Sales, T.; Quested, D.; Grasby, P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch. Gen. Psychiatry, 2004, 61, 134-142. (Pubitemid 38146547)
21. Hietala, J.; Syvalahti, E.; Vuorio, K.; et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet, 1995, 346, 1130-1131.
22. Hietala, J.; Syvalahti, E.; Vilkman, H., et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr. Res., 1999, 35, 41-50. (Pubitemid 29023553)
23. Howes, O.D.; Montgomery, A.J.; Asselin, M.; Murray, R.M.; Grasby, P.M.; McGuire, P.K. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br. J. Psychiatry., 2007, 51, s13-s18. (Pubitemid 350273183)
24. Howes, O.D.; Montgomery, A.J.; Asselin, M. et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry., 2009, 66, 13-20.
25. Lindstrom, L.H.; Gefvert, O.; Hagberg, G. et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol. Psychiatry., 1999, 46, 681-688. (Pubitemid 29401864)
26. Dao-Castellana, M.H.; Paillere-Martinot, M.L.; Hantraye, P.; Attar-Levy, D.; Remy, P.; Crouzel, C.; Artiges, E.; Feline, A.; Syrota, A.; Martinot, J.L. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr. Res., 1997, 23, 167-174. (Pubitemid 27106901)
27. Elkashef, A.M.; Doudet, D.; Bryant, T.; Cohen, R.M.; Li, S.H.; Wyatt, R.J. 6-(18)F-DOPA PET study in patients with schizophrenia: positron emission tomography. Psychiatry Res., 2000, 100, 1-11.
28. Fusar-Poli, P., Meyer-Lindenberg, A. Striatal Presynaptic Dopamine in Schizophrenia, Part II: Meta-Analysis of [18F/11C]-DOPA PET Studies. Schizophr. Bull., 2012 Jan 26.
29. Fusar-Poli, P.; Howes, O.D.; Allen, P.; Broome, M.; Valli, I.; Asselin, M.C.; Montgomery, A.J.; Grasby, P.M.; McGuire, P. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol. Psychiatry, 2011, 16(1), 67-75.
30. Huttunen, J.; Heinimaa, M.; Svirskis, T.; Nyman, M.; Kajander, J.; Forsback, S.; Solin, O.; Ilonen, T.; Korkeila, J.; Ristkari, T.; McGlashan, T.; Salokangas, R.K.; Hietala, J. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol. Psychiatry, 2008, 63(1), 114-117. (Pubitemid 350234886)
31. Allen, P.; Chaddock, C.A.; Howes, O.D.; Egerton, A.; Seal, M.L.; Fusar-Poli, P.; Valli, I.; Day, F.; McGuire, P.K. Abnormal Relationship Between Medial Temporal Lobe and Subcortical Dopamine Function in People With an Ultra High Risk for Psychosis. Schizophr. Bull., 2011 May 2.
32. Shotbolt, P.; Stokes, P.R.; Owens, S.F.; Toulopoulou, T.; Picchioni, M.M.; Bose, S.K.; Murray, R.M.; Howes, O.D. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol. Med., 2011, 41(11), 2331-2338.
33. Lavalaye, J.; Linszen, D.H.; Booij, J.; et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr. Res., 2001, 47, 59-67. (Pubitemid 32121771)
34. Hsiao, M.C.; Lin, K.J.; Liu, C.Y.; Tzen, K.Y.; Yen, T.C. Dopamine transporter change in drug-naive schizophrenia: An imaging study with 99mTc-TRODAT-1. Schizophr. Res., 2003, 65, 39-46.
35. Yang, Y.K.; Yu, L.; Yeh, T.L.; Chiu, N.T.; Chen, P.S.; Lee, I.H. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: A dual-isotope SPECT study. Am. J. Psychiatry, 2004, 161, 1496-1498. (Pubitemid 38989108)
36. Laakso, A.; Vilkman, H.; Alakare, B.; et al. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am. J. Psychiatry, 2000, 157, 269-271. (Pubitemid 30080910)
37. Schmitt, G.J.; Frodl, T.; Dresel, S.; et al. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drugnaive schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci., 2006, 256, 115-121.
38. Fusar-Poli, P.; Meyer-Lindenberg, A. Striatal Presynaptic Dopamine in Schizophrenia, Part I: Meta-Analysis of Dopamine Active Transporter (DAT) Density. Schizophr. Bull., 2012 Jan 26.
39. Sjoholm, H.; Bratlid, T.; Sundsfjord, J. 123I b-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology, 2004, 173, 27-31. (Pubitemid 38591143)
40. Schmitt, G.J.; la Fougere, C.; Dresel, S.; et al. Dual-isotope SPECT imaging of striatal dopamine: First episode, drug naive schizophrenic patients. Schizophr. Res., 2008, 101, 133-141.
41. Tatsch, K.; Scherer, J.; Linke, R.; Kerner, M.; Hahn, K. Decrease of dopamine transporter binding in neuroleptic-free schizophrenic patients assessed with IPT-SPECT (abstr.). J. Nucl. Med., 1999, 40, 31.
42. Laakso, A.; Bergman, J.; Haaparanta, M.; Vilkman, H.; Solin, O.; Sivälahti, E.; Hietala J. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr. Res., 2001, 52, 115-120. (Pubitemid 32947054)
43. Mateos, J.J.; Lomea, F.; Parellada, E.; Font, M.; Fernandez, E.; Pavia, J.; Prats, A.; Pons, F.; Bernardo, M. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology, 2005, 181, 401-406. (Pubitemid 41492210)
44. Mateos, J.J.; Lomea, F.; Parellada, E.; Mireia, F.; Fernandez-Egea, E.; Pavia, J.; Prats, A.; Pons, F.; Bernardo, M. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacol (Berl.), 2007, 191(3), 805-811. (Pubitemid 46355894)
45. Mané, A.; Gallego, J.; Lomea, F.; Mateos, J.J.; Fernandez-Egea, E.; Horga, G.; Cot, A.; Pavia, J.; Bernardo, M.; Parellada, E. A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients. Psychiatry Res., 2011, 194(1), 79-84.
46. Lee, T.; Seeman, P. Elevation of brain neuroleptic/ dopamine receptors in schizophrenia. Am. J. Psychiatry, 1980, 137, 191-197. (Pubitemid 10143768)
47. Mackay, A.V.; Iversen, L.L.; Rossor, M.; Spokes, E.; Bird, E.; Arregui, A.; Creese, I.; Synder, S.H. Increased brain dopamine and dopamine receptors in schizophrenia. Arch. Gen. Psychiatry, 1982, 39, 991-997. (Pubitemid 12020980)
48. Clow, A.; Theodorou, A.; Jenner, P.; Marsden, C.D. Changes in rat striatal dopamine turnover and receptor activity during one year's neuroleptic administration. Eur. J. Pharmacol., 1980, 63, 135-144. (Pubitemid 10105503)
49. Clow, A.; Theodorou, A.; Jenner, P.; Marsden, C.D. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur. J. Pharmacol., 1980, 63, 145-157. (Pubitemid 10105504)
50. Weinberger, D.; Laruelle, M. In: Neurochemical and neuropharmachological imaging in schizophrenia. In: Neuropsychopharmacology-The Fifth Generation of Progress, Davis KL, Charney DS, Coyle J et al., eds Lippincott Williams Wilkins, 2001.
51. Kessler, R.M.; Woodward, N.D.; Riccardi, P.; Li, R.; Ansari, M.S.; Anderson, S.; Dawant, B.; Zald, D.; Meltzer, H.Y. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol. Psychiatry, 2009, 65(12), 1024-1031.
52. Kegeles, L.S.; Slifstein, M.; Xu, X.; Urban, N.; Thompson, J.L.; Moadel, T.; Harkavy-Friedman, J.M.; Gil, R.; Laruelle, M.; Abi-Dargham, A. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol. Psychiatry, 2010, 68(7), 634-641.
53. Laruelle, M.; Martinez, D.; Talbot, P.S.; Adi-Dargham, A. In: Molecular Imaging in psychiatric disorder. In Positon Emission Tomography: Basic science and clinical practice, Edited by Valk P, Bailey DL, Townsend DW, Maisey MN, Springer, 2003.
54. Fujita, M.; Verhoeff, N.P.L.G.; Varrone, A.; Zoghbi, S.S.; Baldwin, R.M.; Jatlow, P.A.; Anderson, G.M.; Seibyl, J.P.; Innis, R.B. Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans. Eur. J. Pharmacol., 2000, 387, 179-188. (Pubitemid 30067814)
55. Laruelle, M.; D'Souza, C.D.; Baldwin, R.M.; Abi-Dargham, A.; Kanes, S.J.; Fingado, C.L.; Seibyl, J.P.; Zoghbi, S.S.; Bowers, M.B.; Jatlow, P.; Charney, D.S.; Innis, R.B. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology, 1997, 17, 162-174. (Pubitemid 27365957)
56. Abi-Dargham, A.; Rodenhiser, J.; Printz, D.; Zea-Ponce, Y.; Gil, R.; Kegeles, L.S.; Weiss, R.; Cooper, T.B.; Mann, J.J.; VanHeertum, R.L.; Gorman, J.M.; Laruelle, M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U S A, 2000, 97, 8104-8109. (Pubitemid 30460780)
57. Carlsson, A.; Carlsson, M.L. Adaptive properties and heterogeneity of dopamine D(2) receptors -pharmacological implications. Brain Res. Rev., 2008, 58, 374-378.
58. Seeman, P., et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc. Natl. Acad. Sci. U S A, 2005, 102, 3513-3518. (Pubitemid 40328076)
59. Skinbjerg, M.; Sibley, D.R., Javitch, J.A.; Abi-Dargham, A. Imaging the high-Affinity state of the dopamine D2 receptor in vivo: fact or fiction? Biochem. pharmacol., 2012, 83, 193-198.
60. Iizuka, Y.; Sei, Y.; Weinberger, D.R.; Straub, R.E. Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J. Neurosci., 2007, 27, 12390-12395. (Pubitemid 350085456)
61. Laruelle, M.; Abi-Dargham, A.; van Dyck, C.H.; et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA, 1996, 93, 9235-9240.
62. Breier, A.; Su, T.P.; Saunders, R.; et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA, 1997, 94, 2569-2574. (Pubitemid 27136916)
63. Abi-Dargham, A.; Gil, R.; Krystal, J.; et al. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am. J. Psychiatry, 1998, 155, 761-767. (Pubitemid 28252654)
64. Laruelle, M.; Abi-Dargham, A.; Gil, R.; Kegeles, L.; Innis, R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol. Psychiatry, 1999, 46, 56-72. (Pubitemid 29296818)
65. Abi-Dargham, A.; Kegeles, L.; Zea-Ponce, Y.; et al. Amphetamine-induced dopamine release in patients with schizotypal personality disorders studied by SPECT and [123I]IBZM. Biol. Psychiatry, 2004, 55, 1001-1006.
66. Brunelin, J.; d'Amato, T.; Van Os, J.; Costes, N.; Suaud-Chagny, M.F.; Saoud, M. Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress. Psychiatry Res., 2010, 181, 130-135.
67. Soliman, A.; O'Driscoll, G.A.; Pruessner, J.; Holahan, A.L.; Boileau, I.; Gagnon, D.; Dagher, A. Stress-induced dopamine release in humans at risk of psychosis: a [11C]raclopride PET study. Neuropsychopharmacology, 2008, 33(8), 2033-2041. (Pubitemid 351832609)
68. Mizrahi, R.; Addington, J.; Rusjan, P.M.; Suridjan, I.; Ng, A.; Boileau, I.; Pruessner, J.C.; Remington, G.; Houle, S.; Wilson, A.A. Increased Stress-Induced Dopamine Release in Psychosis. Biol. Psychiatry, 2012, 71(6), 561-567.
69. Woodward, N.D.; Cowan, R.L.; Park, S.; Ansari, MS.; Baldwin, R.M.; Li, R.; Doop, M.; Kessler, R.M.; Zald, D.H. Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions. Am. J. Psychiatry, 2011, 168(4), 418-426.
70. Lodge, D.J.; Grace, A.A. Developmental pathology, dopamine, stress and schizophrenia. Int. J. Dev. Neurosci., 2011, 29(3), 207-213.
71. Brunelin, J.; d'Amato, T.; van Os, J.; Cochet, A.; Suaud-Chagny, M.F.; Saoud, M. Effects of acute metabolic stress on the dopaminergic and pituitary-Adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophr. Res., 2008, 100(1-3), 206-211.
72. Brunelin, J.; d'Amato, T.; van Os, J.; Dalery, J.; Suaud-Chagny, M.F.; Saoud, M. Serotonergic response to stress: a protective factor against abnormal dopaminergic reactivity in schizophrenia? Eur. Psychiatry, 2007, 22(6), 362-364. (Pubitemid 47398941)
73. Kegeles, L.; Abi-Dargham, A.; Frankle, W.; et al. Increased synaptic dopamine in associative regions of the striatum in schizophrenia. Arch. Gen. Psychiatry, 2010, 67, 231-239.
74. Carlsson, A.; Waters, N.; Holm-Waters, S.; Tedroff, J.; Nilsson, M.; Carlsson, M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia : new evidence. Annu. Rev. pharmacol. toxicol., 2001, 41, 237-260. (Pubitemid 32385889)
75. Brunelin, J.; Szekely, D.; Costes, N.; Mondino, M.; Bougerol, T.; Saoud, M.; Suaud-Chagny, M.F.; Poulet, E.; Polosan, M. Theta burst stimulation in the negative symptoms of schizophrenia and striatal dopamine release. An iTBS- [11C]raclopride PET case study. Schizophr. Res., 2011, 131(1-3), 264-265.
76. Strafella, A.P.; Paus, T.; Barrett, J.; Dagher, A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J. Neurosci., 2001, 21(15), RC157.
77. Hess, E.J.; Bracha, H.S.; Kleinman, J.E.; Creese, I. Dopamine receptor subtype imbalance in schizophrenia. Life Sci., 1987, 40, 1487-1497. (Pubitemid 17040520)
78. Seeman, P.; Bzowej, N.H.; Guan, H.C.; et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology, 1987, 1(1), 5-15. (Pubitemid 19125243)
79. Knable, M.B.; Hyde, T.M.; Herman, M.M.; Carter, J.M.; Bigelow, L.; Kleinman, J.E. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol. Psychiatry, 1994, 36 (12), 827-835
80. Karlsson, P.; Farde, L.; Halldin, C.; Sedvall, G. PET study of D1 dopamine receptor binding in neuroleptic-naïve patients with schizophrenia. Am. J. Psychiatry, 2002, 159(5), 761-767. (Pubitemid 34465049)
81. Okubo, Y.; Suhara, T.; Suzuki, K.; et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature, 1997, 385(6617), 634-636.
82. Kosaka, J., Takahashi, H.; Ito, H.; et al. Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia. Life Sci., 2010, 86(21-22), 814-8.
83. Abi-Dargham, A., Mawlawi, O., Lombardo, I., et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci., 2002, 22 (9), 3708-3719. (Pubitemid 37465776)
84. Martinez, D.; Slifstein, M.; Broft, A.; et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J. Cereb. Blood Flow Metab., 2003, 23, 285-300. (Pubitemid 36307573)
85. Mawlawi, O., Martinez, D.; Slifstein, M.; et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and recision of D2 receptor parameter measurements in ventral striatum. J. Cereb. Blood Flow Metab., 2001, 21, 1034-1057. (Pubitemid 32823740)
86. Gruzelier, J.H. Functional Neuropsychophysiological Asymmetry in Schizophrenia: A Review and Reorientation. Schizophr. Bull., 1999, 25, 91-120. (Pubitemid 29104376)
87. Vollenweider, F.X., Vontobel, P., Hell, D., Leenders, K.L. 5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man-A PET Study with [11C]raclopride. Neuropsychopharmacology, 1999, 20, 424-433. (Pubitemid 29123870)
88. Hirvonen, J., van Erp, T.G., Huttunen, J., Aalto, S., Nagren, K., Huttunen, M., Lönnqvist, J., Kaprio, J., Hietala, J., Cannon, T.D. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch. Gen. Psychiatry, 2005, 62, 371-378. (Pubitemid 40471686)
89. Bracha, H.S., Livingston, R.L., Clothier, J., Linington, B.B., Karson, C.N. Correlation of severity of psychiatric patients' delusions with right hemispatial inattention (left-turning behavior). Am. J. Psychiatry, 1993, 150, 330-332. (Pubitemid 23046526)
90. Levine, J., Martine, T., Feraro, R., Kimhi, R., Bracha, H.S. Medicated chronic schizophrenic patients do not demonstrate left turning asymmetry. Neuropsychobiology, 1997, 36, 22-24. (Pubitemid 27243774)
91. Brunelin, J.; Pouet, E.; Bor, J.; Rivet, A.; Eche, J.; d'amato, T.; Saoud, M. Transcranial magnetic stimulation (rTMS) and negative symptoms of schizophrenia. Ann. Med. Psychol. (Paris), 2010, 168, 422-427.